ProStrakan Launching SANCUSO (Granisetron Transdermal System) in European Union with 3M Drug Delivery Systems as Manufacturer

  ProStrakan Launching SANCUSO (Granisetron Transdermal System) in European
  Union with 3M Drug Delivery Systems as Manufacturer

 First and only treatment targeting chemotherapy-induced nausea and vomiting
                      that doesn’t require a pill or IV

Business Wire

ST. PAUL, Minn. -- September 30, 2013

The European Medicines Agency (EMA) has granted approval for ProStrakan Group
plc to market SANCUSO® (Granisetron Transdermal System) in the European Union
(EU), with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan
begins marketing the product this month in the United Kingdom, Germany and the
Netherlands. Additional European countries are expected to be added in 2014.

Initially introduced in the United States in 2008, SANCUSO is the first and
only treatment for chemotherapy-induced nausea and vomiting that does not
require pills or intravenous (IV) administration. The transdermal patch is
applied to the upper arm and can be worn for seven days, providing continuous
transdermal delivery and eliminating the need to take pills daily to control
nausea and vomiting. This simple-to-use treatment has been proven effective in
patients at risk for chemotherapy-induced nausea and vomiting.

“SANCUSO is a great illustration of the patient-friendly benefits of
transdermal treatment,” said Jim Ingebrand, president and general manager, 3M
Drug Delivery Systems. “We look forward to a continued partnership with
ProStrakan to bring SANCUSO to new markets.”

3M Drug Delivery Systems is applying more than 30 years of transdermal
experience and regulatory expertise to its manufacturing responsibilities for
SANCUSO. The company’s cGMP compliant manufacturing and strength in global
supply chain management ensure reliability and a smooth process from start to
finish for manufacturing partners.

“SANCUSO is already proving to be an important option for patients in the U.S.
suffering from chemotherapy-induced nausea and vomiting,” said Jamie
Blackport, senior vice president of international marketing at ProStrakan. “We
are excited about working together with 3M to bring this important treatment
to patients in the EU.”

While ProStrakan has previously relied on a different manufacturer for the
U.S. supply of SANCUSO, FDA approval is currently pending for the 3M Drug
Delivery Systems manufactured product.

About SANCUSO® (Granisetron Transdermal System)

SANCUSO® (Granisetron Transdermal System) is the first and only 5-HT3 receptor
antagonist available as a transdermal patch for the prevention of CINV. 
SANCUSO transdermal patch is indicated in adults for the prevention of nausea
and vomiting associated with moderately or highly emetogenic chemotherapy, for
a planned duration of 3 to 5 consecutive days, where oral anti-emetic
administration is complicated by factors making swallowing difficult.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company
engaged in the development and commercialization of prescription medicines for
the treatment of unmet therapeutic needs in major markets. ProStrakan is a
subsidiary of Kyowa Hakko Kirin Co. Ltd., the Japan-based global specialty
pharmaceutical company. ProStrakan's head office is located in Galashiels in
Scotland. The company’s development capabilities are centred in Galashiels and
Bridgewater, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of
products are handled by commercial subsidiaries in the UK, US, France,
Germany, Spain, Italy and other EU countries. You can learn more about the
business at: www.prostrakan.com

About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to
develop and manufacture pharmaceutical products using 3M's inhalation,
transdermal or microneedle drug delivery technology. 3M offers a full range of
feasibility, development and manufacturing capabilities to help bring products
to market. Regulatory expertise, quality assurance, operations, marketed
product support and other in-house resources are available for each step of
the development and commercialization process. For more information, please
visit www.3M.com/dds or call 1-800-643-8086.

About 3M

3M captures the spark of new ideas and transforms them into thousands of
ingenious products. Our culture of creative collaboration inspires a
never-ending stream of powerful technologies that make life better. 3M is the
innovation company that never stops inventing. With $30 billion in sales, 3M
employs about 88,000 people worldwide and has operations in more than 70
countries. For more information, visit www.3M.com or follow @3MNews on
Twitter.

3M is a trademark of 3M Company.

Contact:

3M Contacts:
Karwoski & Courage
MaryEllen Columbus, 612-342-9705
m.columbus@creativepr.com
or
3M
Mary Kokkinen, 651-733-8806
3M Public Relations and Corporate Communications
mckokkinen@mmm.com
or
ProStrakan Contact:
Callum Spreng, +44 (0)141 548 5191
callum.spreng@sprengandco.com
 
Press spacebar to pause and continue. Press esc to stop.